AAN 2021 | Neuroimmunological adverse events associated with immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) targeting CTLA-4, PD-1 and PDL-1 have revolutionized the treatment of numerous cancers. However, these therapies are associated with immune-related toxicities, many of which are driven by the same mechanisms underlying the drugs’ efficacy. Karin Woodman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on neuroimmunological adverse events associated with ICI use. A recent retrospective pharmacovigilance study identified many inflammatory adverse events in patients treated with ICIs, including meningitis, encephalitis, myelitis, myasthenia, hypophysitis, and neuropathy. The risk of neurologic complications is increased when ICI therapies are used in combination. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.